VOLUME 44 / SUPPLEMENT 58 / SEPTEMBER 2014
Abstracts / 24th International Congress Munich, Germany 6 –10 September 2014
Online ISSN: 1399-3003
Copyright for individual abstracts remains with the authors. This abstract supplement has been produced electronically by the European Respiratory Society. The European Respiratory Society is not responsible for errors or omissions in content. The ideas and opinions expressed in this publication do not necessarily reflect those of Coe-Truman and the European Respiratory Society. Products mentioned in this publication should not be construed as an endorsement of the product or the manufacturer’s claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. The European Respiratory Society assumes no responsibility for any injury and/or damage to persons or property arising out of or related to any use of the material contained in these abstracts. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. An effort has been made to check generic and trade names, and to verify drug doses. The ultimate responsibility, however, lies with the prescribing physician. Please convey any errors to
[email protected]. Citations should be made in the following way: Authors. Title. Eur Respir J 2014; 44: Suppl. 58, abstract number.
ERS International Congress 2014 Your personal abstract book
Table Of Content 254. Pulmonary hypertension: right ventricle and basic physiology ....................................................................................................................................................................................... 2 2309: Hemodynamic effects of different vasodilators in patients with type II pulmonary hypertension (PH)
................................................................................................................................................................................... 2
Eur Respir J 2014; 44: Suppl. 58
Page 1/2
ERS International Congress 2014 Your personal abstract book
254. Pulmonary hypertension: right ventricle and basic physiology 2309 Hemodynamic effects of different vasodilators in patients with type II pulmonary hypertension (PH) Andrei Bautin¹, Dmitrii Tashkhanov¹, Sergey Datsenko¹, Petr Fedotov¹, Andrei Iakovlev¹, Olga Moiseeva², Maria Sitnikova³ ¹Anaesthesiology, Almazov Federal Medical Research Centre, Saint - Petersburg, Russian Federation; ²Non Coronary Heart Disease, Almazov Federal Medical Research Centre, Saint - Petersburg, Russian Federation; ³Heart Failure, Almazov Federal Medical Research Centre, Saint - Petersburg, Russian Federation Purpose. To evaluate the hemodynamic effects of nitric oxide(NO) and inhaled iloprost in patients with PH associated with left ventricular (LV) systolic dysfunction. Materials and Methods. 72 right heart catheterizations and vasoreactivity tests (VRT) were performed in 58 candidates for heart transplantation. All the patients had heart failure (HF) III-IV NYHA and PH associated with LV systolic dysfunction. NO, 60 ppm for 20 min (43 cases, NO gr.), or inhaled Iloprost 5 mcg (29 cases, iloprost gr.) were used for VRT. Hemodynamic effects were estimated at baseline, then after 20 min period of NO inhalation, or 15 min post the completion of iloprost inhalation. T-test for dependent samples and Fisher's exact test were used for analysis. Results. There were no differences between the groups in age, HF severity or baseline PAmean and PVR. Both vasodilators significantly decreased PVR. PCWP increased in 20 cases (46,5%) in NO gr. and in 7 cases (24,1%) in iloprost gr. (p
